ETTX stock forecast
Our latest prediction for Entasis Therapeutics Holdings, Inc.'s stock price was made on the Jan. 9, 2020 when the stock price was at 4.90$.
In the short term (2weeks), ETTX's stock price should underperform the market by -6.20%. During that period the price should oscillate between -12.36% and +11.86%.
In the medium term (3months), ETTX's stock price should underperform the market by -7.02%. During that period the price should oscillate between -45.71% and +35.19%.Get email alerts
About Entasis Therapeutics Holdings, Inc.
Entasis Therapeutics Holdings, Inc. operates as a clinical stage biopharmaceutical company. It focuses on the discovery and development of novel antibacterial products. The firm develops a portfolio of innovative cures for serious drug-resistant bacterial infections. Its anti-infective discovery platform has produced a pipeline of differentiated programs, which is bacterial infections, including ETX2514SUL (targeting Acinetobacter baumannii infections), ETX0282CPDP (targeting Enterobacteriaceae infections), Non-Beta-lactam PBP inhibitor, and Zoliflodacin. Entasis Therapeutics Holdings was founded in March 2018 and is headquartered in Waltham, MA.
At the moment the company generates 7M USD in revenues.
On its last earning announcement, the company reported a profit of 98.64$ per share.
The book value per share is 4.13$
Three months stock forecastJan. 9, 2020
|Revenue USD||Gross Margin||Operating Income||Operating Margin||Net Income||Earnings Per Share||Dividends||Payout Ratio||Shares||Book Value Per Share||Operating Cash Flow||Cap Spending||Free Cash Flow|